With an increased understanding of GC pathogenesis mechanisms, targeted therapeutic options such as inhibiting HER2, EGFR, VEGF/VEGFR, and CLDN18.2 have become promising topics for research and clinical trials. The gene discussed is ERBB2; the disease is gastric cancer.